This study investigates if reduced muscle mass and muscle function predispose to poor completion of oncological treatment in patients with bladder cancer (including cancer of the renal pelvis, ureter and urethra) and if muscle mass and muscle function change during oncological treatment in these patients. It also evaluates biomarkers for sarcopenia.
Study Type
OBSERVATIONAL
Enrollment
30
Included patients have their muscle mass and muscle function evaluated before start on and after completion of oncological treatment.
Rigshospitalet
Copenhagen, Denmark
RECRUITINGMuscle mass
We will describe if muscle mass at baseline is correlated to completion of planned systemic oncological treatment
Time frame: Up to 36 months
Muscle strength
We will describe if muscle strength at baseline is correlated to completion of planned systemic oncological treatment
Time frame: Up to 36 months
Muscle mass changes during systemic oncological treatment
We will describe if muscle mass change during systemic oncological treatment
Time frame: Up to 36 months
Muscle strength changes during systemic oncological treatment
We will describe if muscle mass change during systemic oncological treatment
Time frame: Up to 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.